Cancer Clinical Trial
Official title:
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386
in combination with either pegylated liposomal doxorubicin or topotecan in subjects with
recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in
combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or
topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject
enrollment and assignment to either cohort will be based on eligibility and the
investigator's discretion.
It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens:
either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in
subjects with recurrent ovarian cancer.
Status | Completed |
Enrollment | 103 |
Est. completion date | June 2015 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically documented recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer - Subjects must have received at least one platinum containing regimen - Radiographically documented progression per RECIST criteria with modifications or progression of CA 125 as adopted by GCIG during or subsequent to the last chemotherapy regimen - Subjects may include those with measurable or non measurable disease - All scans and x-rays used to document measurable or non measurable disease must be done within 28 days prior to enrollment - Female 18 years of age or older at the time the written informed consent is obtained - GOG Performance Status of 0 or 1 - Left Ventricular Ejection Fraction (LVEF) >= institutional lower limit of normal for subjects assigned to cohort A only - Adequate organ function as assessed by laboratory studies (hematological and chemistries) - Life expectancy >= 3 months (per investigator opinion) - Subjects of child bearing potential who have not undergone a bilateral salpingo oophorectomy and are sexually active must consent to use an accepted and effective double barrier non hormonal method of contraception from signing the informed consent through 6 months after last dose of study drug Exclusion Criteria: - Subjects believed to be a higher than average risk of bowel perforation. This includes symptoms of partial or complete bowel obstruction, recent (within 6 months) history of fistula or bowel perforation, subjects requiring total parenteral nutrition and continuous hydration - Previous abdominal /or pelvic external beam radiotherapy - Known history of central nervous system metastases - Subjects with a history of prior malignancy, except: - Malignancy treated with curative intent and with no known active disease present for >= 3 years before study day 1 and felt to be at low risk for recurrence by treating physician - Adequately treated non melanomatous skin cancer or lentigo maligna without evidence of disease - Adequately treated cervical carcinoma in situ without evidence of disease - Prior myeloablative high dose chemotherapy with allogeneic or autologous stem cell (or bone marrow) transplant - History of arterial or deep venous thromboembolism within 12 months prior to enrollment - Clinically significant cardiac disease within 12 months prior to enrollment - Prior treatment with doxorubicin or pegylated liposomal doxorubicin (cohort A subjects) and topotecan (cohort B subjects) - Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine and tacrolimus |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Adelaide | South Australia |
Australia | Research Site | Footscray | Victoria |
Australia | Research Site | Parkville | Victoria |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Liège | |
Belgium | Research Site | Liège | |
Belgium | Research Site | Wilrijk | |
United States | Research Site | Bismarck | North Dakota |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Orlando | Florida |
United States | Research Site | Philadelphia | Pennsylvania |
United States | Research Site | Sacramento | California |
United States | Research Site | St. Louis Park | Minnesota |
United States | Research Site | Tampa | Florida |
United States | Research Site | Tucson | Arizona |
United States | Research Site | Winston Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Australia, Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan | first 4 weeks of treatment | Yes | |
Secondary | To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor burden, CA 125 Response and Progression by GCIG and CA-125 duration of response | Treatment and follow-up phase of study | No | |
Secondary | To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs. | first 4 weeks of treatment | Yes | |
Secondary | To determine the pharmacokinetics of pegylated liposomal doxorubicin (and its metabolite, doxorubicinol), topotecan and AMG 386 (Cmax, AUC, and Cmin for intensive assessment; Cmax and Cmin for sparse assessment). | Treatment and follow-up phase of study | No | |
Secondary | To estimate the incidence of anti AMG 386 antibody formation. | Treatment and follow-up phase of study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|